α-Synuclein: Multiple pathogenic roles in trafficking and proteostasis pathways in Parkinson's disease
- PMID: 38420922
- PMCID: PMC11358363
- DOI: 10.1177/10738584241232963
α-Synuclein: Multiple pathogenic roles in trafficking and proteostasis pathways in Parkinson's disease
Abstract
Parkinson's disease (PD) is a common age-related neurodegenerative disorder characterized by the loss of dopaminergic neurons in the midbrain. A hallmark of both familial and sporadic PD is the presence of Lewy body inclusions composed mainly of aggregated α-synuclein (α-syn), a presynaptic protein encoded by the SNCA gene. The mechanisms driving the relationship between α-syn accumulation and neurodegeneration are not completely understood, although recent evidence indicates that multiple branches of the proteostasis pathway are simultaneously perturbed when α-syn aberrantly accumulates within neurons. Studies from patient-derived midbrain cultures that develop α-syn pathology through the endogenous expression of PD-causing mutations show that proteostasis disruption occurs at the level of synthesis/folding in the endoplasmic reticulum (ER), downstream ER-Golgi trafficking, and autophagic-lysosomal clearance. Here, we review the fundamentals of protein transport, highlighting the specific steps where α-syn accumulation may intervene and the downstream effects on proteostasis. Current therapeutic efforts are focused on targeting single pathways or proteins, but the multifaceted pathogenic role of α-syn throughout the proteostasis pathway suggests that manipulating several targets simultaneously will provide more effective disease-modifying therapies for PD and other synucleinopathies.
Keywords: Parkinson’s disease; autophagy; protein trafficking; synuclein.
Conflict of interest statement
Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
-
Rescue of α-synuclein aggregation in Parkinson's patient neurons by synergistic enhancement of ER proteostasis and protein trafficking.Neuron. 2022 Feb 2;110(3):436-451.e11. doi: 10.1016/j.neuron.2021.10.032. Epub 2021 Nov 17. Neuron. 2022. PMID: 34793693 Free PMC article.
-
Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.J Neurosci. 2016 Jul 20;36(29):7693-706. doi: 10.1523/JNEUROSCI.0628-16.2016. J Neurosci. 2016. PMID: 27445146 Free PMC article.
-
Impaired Autophagic-Lysosomal Fusion in Parkinson's Patient Midbrain Neurons Occurs through Loss of ykt6 and Is Rescued by Farnesyltransferase Inhibition.J Neurosci. 2023 Apr 5;43(14):2615-2629. doi: 10.1523/JNEUROSCI.0610-22.2023. Epub 2023 Feb 14. J Neurosci. 2023. PMID: 36788031 Free PMC article.
-
The Role of α-Synuclein Oligomers in Parkinson's Disease.Int J Mol Sci. 2020 Nov 17;21(22):8645. doi: 10.3390/ijms21228645. Int J Mol Sci. 2020. PMID: 33212758 Free PMC article. Review.
-
The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.J Neurochem. 2016 May;137(3):331-59. doi: 10.1111/jnc.13570. Epub 2016 Mar 23. J Neurochem. 2016. PMID: 26852372 Free PMC article. Review.
Cited by
-
Is There a Place for Lewy Bodies before and beyond Alpha-Synuclein Accumulation? Provocative Issues in Need of Solid Explanations.Int J Mol Sci. 2024 Apr 1;25(7):3929. doi: 10.3390/ijms25073929. Int J Mol Sci. 2024. PMID: 38612739 Free PMC article. Review.
-
α-Synuclein Pathology in Synucleinopathies: Mechanisms, Biomarkers, and Therapeutic Challenges.Int J Mol Sci. 2025 Jun 4;26(11):5405. doi: 10.3390/ijms26115405. Int J Mol Sci. 2025. PMID: 40508212 Free PMC article. Review.
-
Single-nucleus multi-omics of Parkinson's disease reveals a glutamatergic neuronal subtype susceptible to gene dysregulation via alteration of transcriptional networks.Acta Neuropathol Commun. 2024 Jul 2;12(1):111. doi: 10.1186/s40478-024-01803-1. Acta Neuropathol Commun. 2024. PMID: 38956662 Free PMC article.
-
Role of Cellular Senescence in Parkinson's Disease: Potential for Disease-Modification Through Senotherapy.Biomedicines. 2025 Jun 7;13(6):1400. doi: 10.3390/biomedicines13061400. Biomedicines. 2025. PMID: 40564120 Free PMC article. Review.
-
Phosphoproteome modifications and cortical circuit dysfunction are linked to the early-stage progression of alpha-synuclein aggregation.bioRxiv [Preprint]. 2025 Jun 5:2025.01.24.634820. doi: 10.1101/2025.01.24.634820. bioRxiv. 2025. PMID: 39896549 Free PMC article. Preprint.
References
-
- Aarsland D, Kurz MW. 2010. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 289(1– 2):18–22. - PubMed
-
- Abeliovich A, Gitler AD. 2016. Defects in trafficking bridge Parkinson’s disease pathology and genetics. Nature 539 (7628):207–16. - PubMed
-
- Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, and others. 2000. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25(1):239–52. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous